Examining quality of life in patients with generalized anxiety disorder: Clinical relevance and response to duloxetine treatment

Pollack, Mark H.; Endicott, Jean; Liebowitz, Michael R.; Russell, James M.; Detke, Michael J.; Spann, Melissa E.; Ball, Susan; Swindle, Ralph

doi:10.1016/j.jpsychires.2007.11.006

Cited by 28 publications

(24 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At baseline, 89% of patients were impaired on the Sheehan Disability Scale (SDS) global functioning and 95% of patients were impaired on the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF) 23. The study confirmed the belief that patients with GAD have impaired functioning and quality of life.…”

Section: Efficacy In Gadsupporting

confidence: 56%

See 1 more Smart Citation

Duloxetine for the treatment of generalized anxiety disorder: a review

Khan

Macaluso²

2008

NDT

View full text Add to dashboard Cite

Approximately 16 million people in the United States suffer from anxiety disorders alone, while another 12 million experience both anxiety and at least one other psychiatric condition. Generalized anxiety disorder (GAD) has lifetime prevalence rates between 5% and 6%. Treatment of GAD is aimed primarily at symptom reduction. Duloxetine, a serotonin norepinephrine reuptake inhibitor (SNRI), received Food and Drug Administration (FDA) approval for the treatment of GAD in 2007. This article reviews the pharmacologic profi le and seminal clinical trials associated with the FDA indication of duloxetine for GAD. A literature search performed using PubMed with the keywords "duloxetine", "gad", "generalized anxiety disorder", and "venlafaxine XR" yielded 27 articles. We also focused on papers that pooled data from these seminal studies. Data on fi le from Eli Lilly were also reviewed, including data from the Eli Lilly website. Based on this search, duloxetine was found to be an FDA-approved treatment option for GAD that has been studied in several double-blind, placebo-controlled clinical trials. This review of duloxetine will help physicians to interpret clinical studies properly and also help them to make an informed decision about which patients are the most appropriate candidates for a trial of duloxetine.

show abstract

Section: Efficacy In Gadsupporting

confidence: 56%

“…A 2008 study by Pollack et al pooled data from 3 studies to assess if duloxetine improved quality of life in patients meeting DSM-IV-TR criteria for GAD 23. By utilizing comparative norms, the analysis examined the clinical importance of the functional outcomes improvements reported in the above studies.…”

Section: Efficacy In Gadmentioning

confidence: 99%

Duloxetine for the treatment of generalized anxiety disorder: a review

Khan

Macaluso²

2008

NDT

View full text Add to dashboard Cite

show abstract

“…Treatment response was defined a priori as a 50% reduction in scores on the HAM-A. Remission was defined as a HAM-A score r10 (Pollack et al, 2008). Significance was established at po0.05, two tailed tests.…”

Section: Discussionmentioning

confidence: 99%

A multifaith spiritually based intervention for generalized anxiety disorder: a pilot randomized trial

et al. 2010

View full text Add to dashboard Cite

This pilot trial evaluated the efficacy of a multifaith spiritually based intervention (SBI) for generalized anxiety disorder (GAD). Patients meeting DSM-IV criteria for GAD of at least moderate severity were randomized to either 12 sessions of the SBI (n=11) delivered by a spiritual care counselor or 12 sessions of psychologist-administered cognitive-behavioral therapy (CBT; n=11). Outcome measures were completed at baseline, post-treatment, and 3-month and 6-month follow-ups. Primary efficacy measures included the Hamilton Anxiety Rating Scale, Beck Anxiety Inventory, and Penn State Worry Questionnaire. Data analysis was performed on the intent-to-treat sample using the Last Observation Carried Forward method. Eighteen patients (82%) completed the study. The SBI produced robust and clinically significant reductions from baseline in psychic and somatic symptoms of GAD and was comparable in efficacy to CBT. A reduction in depressive symptoms and improvement in social adjustment was also observed. Treatment response occurred in 63.6% of SBI-treated and 72.3% of CBT-treated patients. Gains were maintained at 3-month and 6-month follow-ups. These preliminary findings are encouraging and suggest that a multifaith SBI may be an effective treatment option for GAD. Further randomized controlled trials are needed to establish the efficacy of this intervention.

show abstract

“…Total scores for each summary scale are converted into a percentage of the maximum score possible. The Q-LES-Q shows good reliability and validity (Endicott et al 1993) and has been used widely to evaluate quality of life satisfaction in clinical groups such as those with attention deficit hyperactivity disorder, anxiety disorders, and obsessive compulsive disorder (see Mick et al 2008;Pollack et al 2008, andHuppert et al 2009, respectively).…”

Section: Methodsmentioning

confidence: 99%

A Preliminary Investigation of Quality of Life Satisfaction Reports in Emerging Adults With and Without Developmental Coordination Disorder

2011

View full text Add to dashboard Cite

Developmental coordination disorder (DCD) affects around 5% of the population and is diagnosed on the basis of poor motor coordination. Although we know rather little about the lifetime consequences of this disorder, it is clear that significant difficulties remain through adolescence and into adulthood for the majority. It is also clear that significant psychosocial consequences exist for many individuals with DCD. In the current study, quality of life satisfaction was investigated in a group of emerging adults with and without DCD using the Quality of Life Satisfaction Questionnaire (Endicott et al. Psychopharmacology Bulletin, 29, 321-326, 1993). Overall, the group of adults with DCD reported significantly lower levels of quality of life satisfaction across all domains on the scale. This finding has important implications for consideration of early and later intervention for these individuals, as well as for studies to consider the risk and protective factors at play in long-term outcome with respect to both the motor skills and psychosocial aspects of this disorder.

show abstract

Examining quality of life in patients with generalized anxiety disorder: Clinical relevance and response to duloxetine treatment

Cited by 28 publications

References 29 publications

Duloxetine for the treatment of generalized anxiety disorder: a review

Duloxetine for the treatment of generalized anxiety disorder: a review

A multifaith spiritually based intervention for generalized anxiety disorder: a pilot randomized trial

A Preliminary Investigation of Quality of Life Satisfaction Reports in Emerging Adults With and Without Developmental Coordination Disorder

Contact Info

Product

Resources

About